• Mabwell won China NMPA clearance to start clinical trials of 6MW5311, a LILRB4/CD3 T-cell engager bispecific antibody.
• The candidate targets blood cancers, including AML, CMML, and multiple myeloma.
• Mabwell said 6MW5311 is the first LILRB4/CD3 TCE globally to secure clinical trial approval, following earlier FDA clearance.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mabwell (Shanghai) Bioscience Co. Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202606232000PR_NEWS_USPR_____CN90191) on June 24, 2026, and is solely responsible for the information contained therein.